GERN Stock Cash Flow Statements

Geron Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Geron Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-09-30	2005-09-30	2005-06-30	2005-03-31	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-09-30	2002-06-30	2002-03-31

cash flows from operating activities:
net income	-16,375,000	-19,835,000	-25,352,000	-26,447,000	-67,383,000	-55,390,000	-51,973,000	-44,805,000	-49,227,000	-38,122,000	-42,635,000	-41,051,000	-28,117,000	-30,098,000	-32,017,000	-26,697,000	-29,574,000	-27,824,000	-23,787,000	-19,651,000	-15,824,000	-16,355,000	-29,070,000	-15,180,000	-14,239,000	-10,059,000	-7,300,000	-5,597,000	-6,934,000	-7,186,000	-7,429,000	-6,899,000	-6,405,000	-7,183,000	-3,576,000	-8,637,000	-8,842,000	27,185,000	-9,356,000	-9,315,000	-9,549,000	-8,734,000	-8,440,000	-8,254,000	-8,947,000	-11,897,000	-15,953,000	-18,326,000	-18,739,000	-31,854,000	-19,522,000	-21,088,000	-24,389,000	-59,362,000	-18,344,000	-17,031,000	-16,640,000	-11,045,000	-12,834,000	-13,985,000	1,167,000	-9,837,000	-11,862,000	-3,082,000	-9,688,000	-51,683,000	-5,107,000	-9,288,000	-7,932,000	-7,196,000	-9,008,000	-10,475,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	128,000	131,000	142,000	31,000	262,000	111,000	114,000	108,000	121,000	99,000	80,000	79,000	72,000	57,000	61,000	53,000	53,000	48,000	49,000	49,000	33,000	27,000	29,000	9,000	11,000	15,000	14,000	14,000	15,000	16,000	19,000	19,000	18,000	20,000	21,000	21,000	21,000	17,000	13,000	9,000	9,000	14,000	15,000	93,000	122,000	142,000	193,000	214,000	251,000	344,000	402,000	416,000	418,000	401,000	404,000	407,000	397,000	526,000	511,000	353,000	277,000	250,000	230,000	233,000	240,000	251,000
accretion and amortization on investments	-1,738,000	-2,210,000	-2,402,000	-2,388,000	-2,526,000	-2,367,000	-2,815,000	-3,372,000	-3,236,000	-1,727,000	-956,000	-313,000	108,000	196,000	287,000	359,000	362,000	416,000	431,000	421,000	90,000	-124,000	-251,000	-325,000	-476,000	-482,000	-457,000	-410,000	-135,000	24,000	60,000	69,000	89,000	55,000	68,000	155,000	284,000	494,000	547,000	629,000	765,000	850,000	606,000	301,000	319,000	328,000	542,000	595,000	669,000	889,000	1,102,000	1,205,000	1,226,000	765,000	989,000	905,000	909,000	-599,000	-994,000	-917,000	-717,000	-395,000	331,000	620,000	584,000	944,000
amortization of debt issuance costs/debt discounts	262,000	253,000		402,000	690,000	802,000		255,000	245,000	242,000				349,000
non-cash interest expense on liabilities for sales of future royalties	5,079,000	4,801,000
stock-based compensation for services by non-employees	26,000	15,000	13,000	15,000	15,000	92,000	178,000	439,000	99,000	112,000	124,000	112,000	13,000	15,000	20,000	23,000	23,000	25,000	31,000	22,000	16,000	16,000	18,000	17,000	11,000	22,000	36,000	35,000	49,000	71,000	41,000	44,000	58,000	57,000	28,000	45,000	50,000	83,000	112,000	67,000	23,000	84,000	65,000	83,000
stock-based compensation for employees and directors	6,738,000	7,408,000	6,793,000	6,890,000	12,625,000	4,877,000	4,416,000	7,204,000	3,945,000	2,961,000	2,188,000	2,063,000	2,058,000	1,692,000	2,305,000	2,008,000	1,973,000	1,794,000	1,852,000	1,768,000	1,707,000	1,568,000	1,650,000	1,569,000	1,434,000	1,426,000	1,594,000	1,615,000	1,545,000	1,614,000	1,992,000	2,094,000	2,075,000	1,983,000	2,127,000	2,117,000	2,019,000	2,064,000	2,376,000	2,013,000	2,009,000	2,102,000	1,641,000	1,222,000	886,000	1,348,000	1,263,000	1,362,000	1,391,000	2,717,000	2,366,000	3,847,000	6,319,000	3,276,000	4,322,000	3,051,000	3,069,000
amortization of right-of-use assets	181,000	177,000	174,000	170,000	167,000	164,000	127,000	158,000	154,000	152,000	149,000	146,000	144,000	141,000	165,000	137,000	134,000	132,000		67,000	336,000	244,000
increase in allowance for doubtful accounts	-110,000	131,000
changes in assets and liabilities:
inventory	-12,902,000	-17,508,000	-17,688,000	-19,509,000
accounts receivable	-5,333,000	4,649,000	-7,688,000	-27,133,000
prepaid expenses, interest receivable and other assets	515,000	-1,688,000		-533,000
current and noncurrent liabilities	-863,000	-20,621,000		9,560,000	4,810,000	-9,723,000		5,279,000	17,802,000	-11,997,000		27,982,000	-5,061,000	967,000		1,345,000	8,306,000	-2,515,000				-12,039,000
payment on royalty agreement	-3,023,000	-3,682,000
net cash from operating activities	-27,415,000	-47,979,000	-43,945,000	-58,942,000	-53,478,000	-62,253,000	-40,938,000	-50,839,000	-29,601,000	-46,365,000	-35,181,000	-29,582,000	-28,642,000	-33,974,000	-22,168,000	-22,840,000	-17,814,000	-32,734,000	-12,614,000	-15,449,000	-12,395,000	-26,194,000	-10,366,000	-11,980,000	-8,745,000	-12,738,000	-3,010,000	-6,136,000	-4,495,000	-7,368,000	-4,387,000																		-16,585,000	-21,367,000	-14,273,000	-14,044,000	-12,708,000	-16,155,000	-8,966,000	-9,806,000	-9,365,000	-3,428,000	-10,086,000	-5,869,000	-7,249,000	-7,596,000	-3,915,000	-1,398,000	-7,556,000	-9,987,000	-4,931,000	-6,217,000	-7,561,000	-9,062,000	-6,234,000	-9,210,000
cash flows from investing activities:
purchases of property and equipment	-170,000	32,000	141,000	0	-206,000	-615,000	-64,000	-192,000	-202,000	-372,000	-140,000	-171,000	-70,000	-50,000	-103,000	-94,000	0	-10,000	-11,000	-4,000	-195,000	-191,000	-89,000	-257,000	-22,000	-45,000	-7,000																						-84,000	-217,000	-135,000	-136,000	-124,000	-294,000	-122,000	-27,000	-393,000
purchases of marketable securities	-76,696,000	-46,477,000	-184,791,000	-65,808,000	-160,715,000	-65,618,000	-15,867,000	-104,009,000	-114,107,000	-241,611,000	-160,671,000	-40,287,000	-38,945,000	-18,104,000	-60,952,000	-34,052,000	-57,308,000	-25,122,000	-93,135,000	-37,711,000	-175,442,000	-6,913,000	-51,191,000	-35,868,000	-22,316,000	-44,092,000	-38,645,000	-42,653,000	-87,299,000	-19,768,000	-18,746,000																		-17,895,000	-40,299,000	-33,826,000	-19,370,000	-51,395,000	-87,559,000	-37,029,000	-25,891,000	-32,935,000	-39,714,000	-19,483,000	-56,532,000	-39,147,000	-15,511,000	-21,558,000	-34,776,000	-32,010,000	-12,232,000
proceeds from maturities of marketable securities	97,181,000	98,884,000	81,139,000	65,254,000	124,775,000	100,440,000	63,500,000	99,487,000	69,865,000	63,250,000	179,799,000	50,300,000	41,825,000	48,581,000	69,420,000	28,740,000	88,213,000	61,621,000	71,310,000	50,940,000	38,750,000	39,262,000	44,267,000	42,162,000	41,750,000	53,101,000	39,500,000	33,313,000	20,690,000	17,160,000	28,490,000	28,546,000	28,300,000	37,640,000	35,720,000	28,151,000	43,083,000			52,490,000	28,385,000	24,300,000	17,363,000	22,385,000	23,321,000	27,595,000	36,151,000	26,634,000	37,490,000	47,393,000	45,902,000	30,014,000	53,523,000	23,125,000	43,255,000	36,940,000	34,000,000	35,279,000	55,732,000	43,000,000	41,805,000	58,832,000	46,239,000	46,770,000	24,357,000	15,200,000
net cash from investing activities	20,315,000	52,439,000	-103,511,000	-554,000	-36,146,000	34,207,000	47,569,000	-4,714,000	-44,444,000	-178,733,000	18,988,000	9,842,000	2,810,000	30,427,000	8,365,000	-5,406,000	30,905,000	38,083,000	-21,836,000	13,564,000	-129,206,000	32,158,000	-7,013,000	6,037,000	19,412,000	8,964,000	848,000	-9,349,000	-66,609,000	-2,608,000	9,744,000	7,722,000	-3,854,000	9,358,000										6,049,000	1,207,000	9,658,000	16,266,000	8,776,000	19,511,000	7,686,000	11,942,000	10,507,000	2,004,000	-66,251,000	6,104,000	11,023,000	672,000	-7,236,000	35,896,000	-14,419,000	1,799,000		24,215,000			3,044,000	847,000	-10,830,000	10,182,000	-3,535,000	14,460,000	10,214,000
cash flows from financing activities:
proceeds from issuances of common stock from equity plans	591,000	256,000	5,987,000	3,574,000	16,373,000	6,749,000	3,580,000	1,044,000	573,000	7,875,000	223,000	1,201,000			593,000	0	187,000	17,000	111,000
proceeds from issuance of common stock from offering and pre-funded warrant, net of paid issuance costs				0	-271,000	141,000,000
proceeds from exercise of warrants			976,000	4,000	365,000	49,000	0	28,310,000	17,767,000	59,835,000	11,525,000				0	0	2,467,000	12,000	0																																								0	163,000	15,000,000	0		0	12,500,000
proceeds from employee stock purchase plan				0
net cash from financing activities	1,091,000	256,000	166,163,000	3,578,000	16,833,000	147,798,000	33,280,000	29,354,000	18,340,000	281,047,000	11,923,000	4,778,000			19,639,000	0	12,654,000	16,263,000	-581,000	23,976,000	144,265,000	686,000	10,272,000	8,984,000			8,000	9,087,000	82,320,000	1,553,000	1,074,000	0			90,000	241,000	826,000	210,000	78,000	1,477,000	105,000	105,000	97,620,000	433,000	49,000	11,000	1,000			-4,189,000	4,287,000	144,000	144,000	93,888,000	37,000	198,000	9,992,000	3,922,000	14,000	1,509,000	15,290,000	109,000	77,394,000	3,996,000	13,019,000	649,000	1,170,000	20,914,000	-136,000	-220,000	410,000	-168,000
effect of exchange rates on cash, cash equivalents and restricted cash	3,000	18,000		48,000	-21,000	-10,000		6,000	1,000	-16,000				1,000
net increase in cash, cash equivalents and restricted cash	-6,006,000	4,734,000	18,678,000	-55,870,000	-72,812,000	119,742,000	39,893,000	-26,193,000	-55,704,000	55,933,000					5,836,000	-28,246,000	25,745,000	21,612,000	-35,031,000	22,091,000	2,664,000	6,650,000	-7,107,000	3,041,000					11,216,000	-8,423,000
cash, cash equivalents and restricted cash at the beginning of the period	0	80,876,000	0	0	0	71,138,000	0	0	0	57,209,000	0	0	0	35,235,000	0	0	0	10,288,000	0	0	0	13,914,000	0	0	0	10,844,000	0	0	0	16,603,000
cash, cash equivalents and restricted cash at the end of the period	-6,006,000	85,610,000	18,678,000	-55,870,000	-72,812,000	190,880,000	39,893,000	-26,193,000	-55,704,000	113,142,000	-4,258,000	-14,954,000	44,732,000	31,689,000	5,836,000	-28,246,000	25,745,000	31,900,000	-35,031,000	22,091,000	2,664,000	20,564,000	-7,107,000	3,041,000	10,910,000	7,070,000	-2,154,000	-6,398,000	11,216,000	8,180,000
amortization of debt issuance costs/debt discount											224,000	399,000					194,000	180,000
loss of extinguishment of debt
interest and other receivables
prepaid expenses and other assets
deposit and other assets
accounts payable
accrued compensation and benefits
accrued liabilities
operating lease liabilities
proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs											0	0							0	-610,000
proceeds from sale of future royalties
proceeds from debt financing, net of paid debt issuance costs and debt discounts															14,895,000				-692,000
repayment of debt
net effect of exchange rates on cash, cash equivalents and restricted cash
current and noncurrent assets						-819,000		-16,105,000	496,000	1,915,000		-18,999,000	1,786,000	-7,293,000		-321,000	715,000	-3,757,000		-2,952,000	140,000	249,000		-1,013,000	1,146,000	-1,532,000
net gain on exchange and sales of equity investment																			0
prepaid and other current assets
proceeds from sales of equity investment															0	0	0	1,594,000	0
proceeds from issuances of common stock from at market offerings, net of paid issuance costs															4,151,000	0	0	16,234,000	0	0
proceeds from issuance of common stock from public offering and pre-funded warrant, net of paid issuance costs								0	0	213,337,000
debt discount and issuance costs for debt financing												-61,000
gain on sales of available for sale securities																			0
change in fair value of equity investment, including foreign currency translation																			24,000	92,000	-499,000	220,000	-16,000	209,000	106,000	-103,000	266,000	-175,000
amount due to janssen biotech, inc.																			0	0
proceeds from sales of securities available for sale																			0	0
gain on sales of equity investment																0	0	-1,233,000
proceeds from debt financing
net effect of unrealized losses and exchange rates on cash, cash equivalents and restricted cash												8,000
net change in cash, cash equivalents and restricted cash												-14,954,000	44,733,000	-3,547,000
amortization related to 401(k) contributions																							0	0	0	9,000	-1,000	0	0	10,000	0	0	0	32,000	3,000	4,000	53,000	3,000	4,000	154,000	23,000	64,000	12,000	-16,000	362,000	103,000	55,000	109,000	172,000	79,000	178,000	217,000	235,000	133,000	162,000	159,000	193,000	89,000	57,000	76,000	41,000
gain on sale of marketable securities
proceeds from sale of marketable securities
proceeds from sales of marketable securities
amortization of right-of use-assets
other current and noncurrent liabilities																				4,883,000																												1,795,000	-1,783,000		1,024,000	217,000	154,000		731,000	94,000	208,000		-1,352,000	1,965,000	648,000	-116,000	4,623,000	645,000	-1,085,000	-1,768,000
gain on sale of available for sale securities
proceeds from issuance of common stock from equity plans
proceeds from issuances of common stock from financings																						686,000
loss on retirement/sales of property and equipment
prepaid assets
proceeds from issuances of common stock under equity plans
operating lease expense																								170,000
current liabilities																								2,564,000	2,928,000	-2,034,000		-438,000
proceeds from issuances of common stock, net of issuance costs																								8,984,000				9,087,000	82,320,000	1,553,000																	1,000												14,000	1,346,000	290,000	109,000	89,924,000	4,041,000	563,000		1,242,000
net decrease in cash, cash equivalents and restricted cash																										-3,774,000
gain on retirement/sales of property and equipment																															0										0
proceeds from sales of property and equipment																																												1,000,000
loss on retirement of property and equipment																																	0	5,000
current assets																												-1,180,000
change in fair value of equity investment																														125,000
other current and noncurrent assets																														89,000														-344,000	903,000	345,000	77,000	480,000	1,384,000		312,000	1,088,000	2,157,000		1,575,000	904,000	1,299,000		1,147,000	-47,000	455,000	1,345,000	1,295,000	330,000	204,000	-2,942,000
other current liabilities																														-2,131,000		-5,304,000	-322,000	3,727,000	208,000	453,000	24,000
loss on sales of marketable securities
unrealized gain on derivatives																																																									-58,000		247,000	36,000	-14,805,000
accrued collaboration charges
deferred revenue
restricted cash transfer																																																		0	0			0	0								0
proceeds from sales/calls of marketable securities
proceeds from issuances of common stock																															1,074,000	0
net increase in cash and cash equivalents																																		2,051,000															2,926,000			-3,393,000	-10,560,000			1,415,000	1,299,000	-6,742,000			9,840,000					-6,294,000	-2,914,000	3,867,000	2,485,000	-12,817,000	8,636,000	836,000
cash and cash equivalents at the beginning of the period																															0	0	0	12,810,000	0	0	21,248,000	0	0	42,796,000	0	0	12,990,000	0	0	22,063,000	0	0	16,105,000		0	0	45,972,000		0	0	34,601,000		0	0	135,882,000	0	0	0	9,846,000	12,823,000	0	0	4,604,000	0	0	18,773,000
cash and cash equivalents at the end of the period																															6,431,000	3,298,000	-8,255,000	14,861,000	-2,316,000	-4,603,000	12,802,000	1,025,000	5,616,000	10,182,000	-1,920,000	-1,804,000	11,324,000	757,000	-6,671,000	15,505,000	1,885,000	-4,908,000	19,031,000		1,956,000	-3,393,000	35,412,000		-2,825,000	1,415,000	35,900,000		25,824,000	-18,779,000	145,722,000	35,681,000	97,694,000	14,079,000	7,530,000	6,529,000	-2,914,000	3,867,000	7,089,000	-12,817,000	8,636,000	19,609,000
other current assets																																				206,000	813,000
net decrease in cash and cash equivalents																																																																	-2,316,000
supplemental disclosure of non-cash investing activities:
net unrealized gain on marketable securities																																		-18,000	-65,000	50,000	253,000
gain on sales of property and equipment
proceeds from issuance of common stock, net of issuance costs																																			90,000	241,000	826,000	210,000	78,000	1,477,000	105,000	105,000	97,620,000	433,000	49,000	11,000
recognition of deferred revenue
proceeds from sales and maturities of marketable securities																																						49,752,000
loss on write-downs of property and equipment																																												0
unrealized (gain) loss on derivatives																																																							97,000
unrealized loss on derivatives
translation adjustment																																															153,000	0	16,000	-5,000	-8,000	0	12,000	-8,000	15,000	0	-3,000	1,000				5,000	0	-10,000	-27,000	2,000
gain on sale of property and equipment
issuance of common stock in exchange for services by non-employees																																														24,000	42,000	30,000	80,000		111,000	126,000	270,000		840,000	1,328,000	865,000
proceeds from sale of property and equipment																																														104,000	18,000							0	0
accretion of discount on long-term debt																																																		18,000
interest expense on long-term debt
issuance of common stock for acquired in-process research and development																																																			0	0	594,000
loss on equity method investment
proceeds from sale of investments in licensees
proceeds from issuance of long-term debt																																																		2,140,000
issuance of common stock for acquired in-process research and
development
unrealized gain on fair value of derivatives																																																	-26,000	-73,000	-291,000	-240,000	-39,000
proceeds from issuances of common stock and warrants, net of issuance costs																																																			5,000	144,000	144,000		37,000	198,000	9,992,000
cash flows from operating activities
loss on debt extinguishment
loss on retirement/sale of property and equipment																																																							0
loss on impairment of excess equipment
loss on sale of marketable securities
issuance of common stock in connection with acquired
in-process research technology
issuance of common stock and warrants in exchange for
services by non-employees
loss on investments in licensees																																																		0	0	168,000	335,000	1,212,000	243,000	496,000	396,000
deposits and other assets
accrued restructuring charges
advance payment from related party for research
and development
cash flows from investing activities
loan to related party
investment in licensee
proceeds from sale of investment in licensees
cash flows from financing activities
repayment of long-term debt
distribution to ta therapeutics, ltd. shareholder
proceeds from issuance of common stock and warrants, net of issuance costs
cash and cash equivalents, at beginning of year
cash and cash equivalents, at end of year
supplemental disclosure of cash flow information
cash paid for interest
gain on retirement/sale of property and equipment
stock issuance obligation for acquired in-process research and
issuance of common stock and warrants in exchange for services																																																															1,478,000	305,000	2,725,000
by non-employees
accrued compensation
advance payment from related party for research and development																																																										-409,000	-398,000
repurchase of common stock
investments in licensees
gain on sale of fixed assets
amortization of intangible assets, principally research related																																																														0	189,000	188,000	189,000	716,000
research funding payments
proceeds from sale of fixed assets
capital expenditures																																																										-891,000	-353,000	-887,000	-859,000	-156,000	-469,000	-345,000	-126,000	-125,000	-100,000	-111,000	-46,000	-51,000	-15,000	-259,000
free cash flows																																																										-4,319,000	-10,439,000	-6,756,000	-8,108,000	-7,752,000	-4,384,000	-1,743,000	-7,682,000	-10,112,000	-5,031,000	-6,328,000	-7,607,000	-9,113,000	-6,249,000	-9,469,000
payments of obligations under capital leases and equipment loans
stock-based compensation in exchange for services by non-employees																																																											586,000	1,512,000	2,735,000
stock-based compensation for awards to employees and directors																																																											2,934,000	2,569,000	2,922,000
loss recognized under equity method investments
loss on equity investments in licensees																																																										43,000	0	35,000	28,000
stock-based compensation for stock grants to employees																																																														0
accretion of interest on research funding obligation																																																															0	122,000	123,000	123,000
unrealized (gain) loss on fair value of derivatives
notes receivable from related parties
equity investments in licensees
proceeds from sales of marketable equity investments in licensees
accrued research funding obligation																																																														0	-222,000	-724,000	-871,000
payments of obligations under equipment loans																																																														0	-30,000	-45,000	-44,000	-51,000	-72,000	-102,000	-137,000	-224,000	-215,000	-222,000
issuance of common stock and warrants in exchange for services by non-employees																																																														117,000
stock-based compensation for options to employees and directors																																																														996,000
amortization of deferred compensation																																																														40,000	33,000	27,000	53,000	34,000
realized gain on equity investments in licensees																																																														-1,000		-52,000	-3,000	-18,000
proceeds from sales of equity investments in licensees																																																															0
gain on sale of fixed asset
proceeds from sale of fixed asset
net cash (used in)/provided by investing activities																																																																	-7,779,000
net (decrease)/increase in cash and cash equivalents
(gain) / loss on sale of fixed asset
issuance of common stock in exchange for acquired research technology
realized (gain)/loss on equity investments in licensees
net increase/(decrease) in cash and cash equivalents																																																															97,694,000
loss on sale of fixed asset
proceeds from sale of equity investment in licensee																																																																		201,000
adjustments to reconcile net income to net cash from operating
activities:
interest for convertible debentures
conversion expense related to modification of series d
convertible debentures and warrants
issuance of common stock in exchange for acquired research
technology
stock-based compensation
realized loss on equity investments in licensees
issuance of common stock in exchange for acquired in-process research technology																																																																		45,150,000
issuance of common stock in exchange for services																																																																		100,000
accrued research funding payments																																																																		-896,000					-689,000	-527,000
proceeds from issuance of common stock																																																																		700,000			1,000	4,000	127,000	54,000
proceeds from equipment loans																																																																						0
purchases of securities available-for-sale																																																																						-17,200,000
proceeds from sales/calls of securities available-for-sale
proceeds from maturities of securities available-for-sale																																																																						12,500,000	19,276,000	11,000,000

We provide you with 20 years of cash flow statements for Geron stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Geron stock. Explore the full financial landscape of Geron stock with our expertly curated income statements.

The information provided in this report about Geron stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.